{"id":"W4404165262","doi":"10.1158/1078-0432.ccr-24-1612","title":"Randomized Phase II Study of Durvalumab with or without Tremelimumab in Patients with Metastatic Castration-Resistant Prostate Cancer","year":2024,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of British Columbia; University of Toronto; Sunnybrook Hospital; Kingston Health Sciences Centre; Canadian Cancer Society; CancerCare Manitoba; University of Manitoba; Juravinski Cancer Centre; Hamilton Health Sciences; Baker Hughes (Canada); Canadian Centre for Applied Research in Cancer Control; University Health Network; Saskatchewan Cancer Agency; Occupational Cancer Research Centre; Ottawa Hospital; Sunnybrook Health Science Centre; Kelowna General Hospital; London Health Sciences Centre; Interior Health; Princess Margaret Cancer Centre; BC Cancer Agency; Queen's University; Spinal Cord Injury BC","funders":"Canadian Cancer Society","keywords":"Durvalumab; Tremelimumab; Prostate cancer; Medicine; Oncology; Castration; Internal medicine; Prostate; Flutamide; Cancer; Randomized controlled trial; Immunotherapy; Hormone; Androgen receptor; Nivolumab","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001805228,0.001600945,0.002194477,0.0003123224,0.0003792994,0.0009172313,0.001020669,0.001172266,0.005810196],"category_scores_gemma":[0.001139947,0.0007317889,0.001088611,0.0003103873,0.001030046,0.0008333304,0.0003341878,0.002687419,0.001013721],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00100559,"about_ca_system_score_gemma":0.001443124,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006690756,"about_ca_topic_score_gemma":0.002439049,"domain_scores_codex":[0.9994228,0.0003051183,0.00002723746,0.0001031765,0.00004120574,0.0001004206],"domain_scores_gemma":[0.9991641,0.0001506359,0.0001580008,0.00009060709,0.00004565771,0.0003909483],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9377981,0.02560767,0.001761006,0.0003453282,0.0006564247,0.00006648785,0.0001052664,0.0005354913,0.01120547,0.00019161,0.000999267,0.02072785],"study_design_scores_gemma":[0.8864074,0.1096762,0.001882442,0.000009601854,0.0001545001,0.00004407957,0.00001851646,0.0003537469,0.0007220071,0.00009686215,0.0006254609,0.000009128077],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9917787,0.0009252537,0.0005031071,0.0004699281,0.0002471183,0.004070181,0.0007562573,0.00007667226,0.001172855],"genre_scores_gemma":[0.9894536,0.0006730927,0.001508683,0.0008045446,0.0002229532,0.003589485,0.001115508,0.0000254864,0.002606759],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005810196,"threshold_uncertainty_score":0.01943707,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2214674561537067,"score_gpt":0.5506320744122234,"score_spread":0.3291646182585167,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}